KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Accumulated Expenses (2016 - 2018)

NovoCure's Accumulated Expenses history spans 5 years, with the latest figure at $16.7 million for Q4 2018.

  • On a quarterly basis, Accumulated Expenses rose 25.85% to $16.7 million in Q4 2018 year-over-year; TTM through Dec 2018 was $16.7 million, a 25.85% increase, with the full-year FY2018 number at $16.7 million, up 25.85% from a year prior.
  • Accumulated Expenses hit $16.7 million in Q4 2018 for NovoCure, up from $13.3 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for NVCR hit a ceiling of $16.7 million in Q4 2018 and a floor of $5.8 million in Q4 2014.
  • Historically, Accumulated Expenses has averaged $10.3 million across 5 years, with a median of $8.3 million in 2015.
  • Biggest five-year swings in Accumulated Expenses: fell 8.68% in 2016 and later surged 76.14% in 2017.
  • Tracing NVCR's Accumulated Expenses over 5 years: stood at $5.8 million in 2014, then skyrocketed by 41.26% to $8.3 million in 2015, then fell by 8.68% to $7.5 million in 2016, then surged by 76.14% to $13.3 million in 2017, then grew by 25.85% to $16.7 million in 2018.
  • Business Quant data shows Accumulated Expenses for NVCR at $16.7 million in Q4 2018, $13.3 million in Q4 2017, and $7.5 million in Q4 2016.